|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||77.91 - 78.74|
|52 Week Range||61.01 - 82.27|
|Beta (3Y Monthly)||1.28|
|PE Ratio (TTM)||23.32|
|Earnings Date||Nov 18, 2019 - Nov 22, 2019|
|Forward Dividend & Yield||0.66 (0.84%)|
|1y Target Est||82.58|
Agilent Technologies Inc. (NYSE:A) announced today that Professor Hualiang Jiang has received an Agilent Thought Leader Award. Professor Jiang directs the Shanghai Institute of Materia Medica at the Chinese Academy of Sciences and is a leading researcher in the area of medicinal chemistry and computational drug design.
Agilent Technologies, Inc. (NYSE:A) today announced that a quarterly dividend of 16.4 cents per share of common stock will be paid on Oct. 23, 2019 to all shareholders of record as of the close of business on Oct. 1, 2019. Agilent Technologies Inc. (NYSE:A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers' most challenging questions.
Riding on the momentum of its recent initial public offering, a Triangle gene therapy company is launching its second potential cancer treatment into clinical trials.
Agilent (A) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Moody's Investors Service ("Moody's") assigned a Baa2 rating to the proposed offering of senior unsecured notes of Agilent Technologies Incorporated ("Agilent"). There are no changes to Moody's existing ratings of Agilent including the Baa2 senior unsecured long-term rating. The proposed offering does not have a material effect on Agilent's financial leverage.
Agilent Technologies, Inc. (NYSE:A) today announced the pricing of an underwritten, registered public offering of a series of its senior notes in an aggregate principal amount of $500 million. The offering is being conducted under an automatic shelf registration statement on file with the Securities and Exchange Commission. The estimated net proceeds of the offering are expected to be approximately $492.8 million.
(Bloomberg) -- U.S. investment-grade bond issuance is hitting $74 billion for this week, the most for any comparable period since records began in 1972. Thursday’s $20 billion total adds to the $54 billion already sold, thrashing the week’s forecast of $40 billion.With a rally in Treasuries pushing the high-grade bond yield to a three-year low of just 2.77%, companies are borrowing cheap money now to refinance more expensive debt, spurred by a positive tone in global markets. Thursday’s haul includes food and beverage giant Mondelez International Holdings Netherlands BV and Agilent Technologies Inc. Financial firms are also active, with the likes of JPMorgan Chase & Co. and Standard Chartered Plc selling debt.The prior record for investment-grade bond issuance was $66 billion in the week of Sept. 9, 2013 when Verizon Communications Inc. sold $49 billion of bonds in eight parts, the biggest company debt offering ever.Despite the glut, secondary markets have rallied and borrowers have been able to raise more than initially targeted without paying up. Apple Inc. on Wednesday set out to get $4 billion to $5 billion before pricing a total of $7 billion in new bonds. Average new issue concessions were less than 3 basis points, down from 6 basis points on Tuesday, which was also a heavy issuance day.The week’s not over, though issuers generally stay away on a Friday, especially when there’s a U.S. payrolls report.To contact the reporters on this story: Brian Smith in New York at firstname.lastname@example.org;Michael Gambale in New York at email@example.comTo contact the editors responsible for this story: James Crombie at firstname.lastname@example.org, Nikolaj GammeltoftFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Some of the biggest names in gene editing are on Colorado's Front Range, and they're looking to transform how disease is treated.
Agilent Technologies Inc. (NYSE:A) announced today that Professor Hyun Joo An has received an Agilent Thought Leader Award in support of her work in glycomics and biopharmaceutical applications. Dr. Hyun Joo An is a professor at the Graduate School of Analytical Science and Technology, Chungnam National University, in Daejeon, South Korea. “By supporting the work of leading researchers like Professor An, Agilent is contributing to advance the fields of glycan analysis, biopharmaceutical characterization, and quality control,” stated executive sponsor of the award Kevin Killeen, Ph.D., Business Transition Manager for Agilent-ProZyme.
Agilent Technologies, Inc. (NYSE:A) today announced the launch of its 18th annual Corporate Social Responsibility (CSR) report which discusses sustainability activities and progress. The publication summarizes the many ways that Agilent delivers on its commitment to key UN Sustainable Development Goals, best-in-class product innovation, environmental impact reductions, and ground-breaking philanthropic initiatives. “At Agilent, we have a longstanding commitment to advancing the quality of life,” said Mike McMullen, president and CEO of Agilent.
Beyond Meat is just the beginning of a new emerging cohort of innovative companies. These innovators are changing how we feed the planet without consuming more of its resources.
Is Agilent Technologies, Inc. (NYSE:A) a good dividend stock? How can we tell? Dividend paying companies with growing...
Agilent Technologies Inc. (NYSE:A) today announced it has completed the acquisition of BioTek Instruments, a global leader in the design, manufacture and distribution of innovative life science instrumentation. The BioTek acquisition expands Agilent’s growing presence and expertise in cell analysis and strengthens the company’s position in the large and growing immuno-oncology and immunotherapy areas. The combined portfolio will allow Agilent to deliver a range of unique cell analysis workflows to provide customers the ability to obtain deeper, more reliable insights across a variety of cell analysis applications.
IBD Stock Of The Day: Keysight Technologies soared into a buy zone Thursday after crushing earnings estimates. Wall Street hailed the electronic design and testing company.